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Abstract
Splicing is an essential cellular process to generate mature transcripts from pre-mRNA. It requires the splice
factor U1 small nuclear ribonucleoprotein (U1), which promotes exon recognition by base-pairing interaction
with the splice donor site (SD). After U1 dissociation, exon recognition is maintained by U6 small nuclear
ribonucleoproteins (U6). It has been shown that SD mutations lower the binding affinity of U1 and cause splice
defects in about 10% of patients with monogenetic diseases. U1 isoforms specifically designed to bind the
mutated SD with increased affinity can correct these splice defects. We investigated the applicability of this gene
therapeutic approach for different mutated SD positions. A minigene-based splicing assay was established to
study a typical SD derived from the gene BBS1. We found that mutations at seven SD positions caused splice
defects. In four cases, mutation-adapted U1 isoforms completely corrected these splice defects. Partial correction
was found for splice defects induced by the mutation at SD position + 5. The limited therapeutic efficacy at this
position was alleviated by applying a combined treatment with mutation-adapted U1 and U6. The sequence
complementarity between U6 and three SD positions ( + 4, + 5,and + 6) was relevant for the outcome of the
therapy. Between 30 and 100% of the normal transcripts can be restored. The treatment significantly decreased
both exon skipping and intron retention. Massive missplicing of off-target transcripts was not detected. Our
study helps to assess the therapeutic efficacy of mutation-adapted U snRNAs in gene therapy and illustrates
their strong potential to correct splice defects, which cause many different inherited conditions.
Introduction
Splicing of pre-mRNAs involves excision of introns andligation of exons. This process generates mature tran-
scripts that serve as templates for protein translation. Re-
moval of introns from the pre-mRNA requires the recognition
of splice sites. These short and poorly conserved sequences
are located at the 5’ and 3’ end of introns and define exonic
boundaries (Wang and Burge, 2008). Spliceosomal compo-
nents called uridine-rich small nuclear ribonucleoproteins (U
snRNPs) dynamically interact with splice sites to ensure cor-
rect exon recognition (Wahl et al., 2009). For the vast majority
of transcripts, exons and introns are recognized by the U
snRNPsU1, U2, U4, U5, andU6. EachU snRNP is formed by a
complex of different proteins and a U-specific small nuclear
RNA (snRNA) (Will and Luhrmann, 2001).
At the initial steps of the splicing process, U1 is recruited
to the splice donor site (SD). The U1 snRNA, which is part of
the splice factor U1, binds to the SD through Watson-Crick
base-pairing (Zhuang and Weiner, 1986). This involves the
last three nucleotides of the exon (positions - 3 to - 1) and
the first six nucleotides of the downstream intron (positions
+ 1 to + 6) (Lund and Kjems, 2002). In addition to these early
interactions at the SD, other splicing factors including the U2
snRNP are recruited to the splice acceptor site, forming a
complex with U1 across the same exon in vertebrates, a
process called exon definition (Schneider et al., 2010). After
initial formation of this cross-exon complex, a preassembled
heterotrimeric complex containing U4, U5, and U6 snRNPs
(U4/U6.U5 tri-snRNP) is recruited. This leads to the transi-
tion of the cross-exon complex into a complex that forms
across the upstream intron, thus called cross-intron complex.
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It activates the spliceosome to accomplish the first catalytic
steps of the splicing process, which subsequently leads to
dissociation of U1 and U4 snRNPs (Wahl et al., 2009).
Thereafter, correct recognition of the exon at 5’ splice sites is
assured through the interaction of the U6 snRNA (U6) with
nucleotides at positions + 4 to + 6 of the SD (Kandels-Lewis
and Seraphin, 1993; Lesser and Guthrie, 1993). This interac-
tion is maintained until the second catalytic step in the
splicing process has been carried out and all U snRNPs are
released from the mature transcript to be recycled for addi-
tional rounds of splicing (Wahl et al., 2009).
Gene therapeutic approaches have been successfully ap-
plied to several animal models of human diseases. An in-
creasing number of clinical trials further document the need
for treatment options in genetic diseases. Indeed, around
15% to 20% of all point mutations in patients affect splice
sites and are a major cause of monogenetic diseases
(Krawczak et al., 1992; Faustino and Cooper, 2003). Muta-
tions of the SD have been found in many genes and were
associated with the vast majority of inherited human disor-
ders (for reference see the human gene mutation database
online). Mutations in splice sites result in exon skipping,
intron retention, or activation of cryptic splice sites, which
leads to a reduction or absence of correctly spliced tran-
scripts (Faustino and Cooper, 2003). The majority of muta-
tions found in the SD affect positions - 1, + 1, + 2, and + 5.
Nucleotides at these SD positions are more conserved than
the others (Buratti et al., 2007; Krawczak et al., 2007).
It has been documented that mutations reduce the inter-
action of U1 with the SD, subsequently causing aberrant
splicing (Zhuang and Weiner, 1986). We and others showed
that an increase in complementary of the U1 with the mu-
tated SD corrects splice defects following virus-mediated
treatment of patient-derived cell lines (Hartmann et al.,
2010; Glaus et al., 2011; Schmid et al., 2011). The efficacy of
this approach was tested for mutations at SD position - 1,
+ 1, or + 3.
The study presented here uses a typical splice donor site to
analyze the applicability of the U1 approach to treat SD
mutations at several different positions. We further suggest
that U6 is a promising candidate molecule in gene therapy
and show that only a co-application of adapted U1 and U6
isoforms corrects the splice defect caused by the mutation at
SD position + 5.
Materials and Methods
Site-directed mutagenesis and cloning
Polymerase chain reactions (PCRs) were performed using
Pfu-polymerase (Promega, Du¨bendorf, Switzerland). Se-
quences of primers used to produce mutated minigenes and
different U snRNA constructs are shown in Supplemen-
tary Table 1 (Supplementary Material available online at
www.liebertonline.com/hum). Introduced nucleotide ex-
changes were selected on the basis of their conservation
in the SD and their potential to disturb the binding affinity
to U1.
The minigene construct of the wild-type BBS1 gene in-
cludes the genomic region of intron 4 through 7. The wild-
type BBS1 minigene was previously characterized (Schmid
et al., 2011). Mutagenesis was performed as described by
Tanner et al. 2009. Briefly, two PCR products were amplified
from the minigene construct with primers containing the
mutation to be analyzed. The two overlapping products
were joined using primers pSPL3_MCS_F and
pSPL3_MCS_R. PCR products containing the different SD
mutations were subcloned into the pJet1 or pJet1.2 cloning
vector (Fermentas, Le Mont sur Lausanne, Switzerland) and
transferred into pSPL3 using XhoI and BamHI restriction
sites.
The promoter and coding region of U6 snRNA was am-
plified from genomic DNA of human skin fibroblasts using
primers U6_XbaI_fwd and U6_EcoRI_R. The XbaI- and
EcoRI-digested PCR product was inserted into the cloning
vector pGem3 using T4-Ligase (Promega). The pGem3 vector
containing the genomic region encoding the U6 snRNA was
used as PCR template to modify the U6 SD-binding sequence
with primers carrying specific sequence alterations. Over-
lapping fragments were joined with primers binding to the
T7 and SP6 promoter and cloned in the pGem3 vector.
Constructs expressing different isoforms of U1 were
produced as described previously (Tanner et al., 2009).
Cell culture and transfection
COS-7 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 1.3% L-glutamine, and 1.1% penicillin/strep-
tomycin (PAA; Chemie Brunschwig AG, Basel, Switzerland)
at 37C, 5% CO2. One to 4*105 cells were co-transfected with
either 2.4 lg wt or mut minigene and 2.4 lg of a U1 expres-
sion construct using branched polyethyleneimine (PEI)
(Sigma-Aldrich, Steinheim, Germany). Triple transfections
with U6 snRNA isoforms were performed with 1.6 lg of each
construct. Cells were harvested two days after transfection
and each experiment was replicated three to eight times.
RNA extraction and RT-PCR analysis
Total RNA was extracted from COS-7 cells using the
NucleoSpin RNA II kit (Macherey-Nagel, Oensingen,
Switzerland). To remove genomic DNA, RNA samples were
treated with DNase using the DNA-free KitTM (Applied
Biosystems, Rotkreuz, Switzerland). RNA was randomly
primed and reverse transcribed into cDNA using Superscript
III reverse transcriptase following the manufacturer’s pro-
tocol (Invitrogen, Basel, Switzerland). Minigene-derived
splicing of BBS1 was analyzed by reverse transcriptase PCR
(RT-PCR) as described previously (Schmid et al., 2011).
To search for potential side effects of the treatment, off-
target transcripts were analyzed by RT-PCR. Potential
binding sides of adapted U1 and U6 were identified by
searching for perfect or almost-perfect sequence comple-
mentarity (at least seven base pairs [bp]) with the genomic
reference sequences of various disease-associated transcripts.
RNA extraction, cDNA construction, and RT-PCR from COS-
7 cells transfected with different adapted U1 and U6 isoforms
was performed as described above. Primer names and se-
quences are provided in Supplementary Table 1.
Semi-quantitative analysis of spliced products
The amount of amplified RT-PCR products showing either
exon 5 skipping, intron 5 retention, or correct splicing of
BBS1 was determined for each treatment using an
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electrophoretic analysis system (2100 Bioanalyzer; Agilent,
Basel, Switzerland). The level of each splice product was
normalized to the amount found in control treatments (wild-
type U6 in combination with either fully adapted U1 or the
wild-type U1) and averaged from eight independent trans-
fections. The error bars represent confidence intervals of
95%.
Results
Position-dependent effects of splice donor
site mutations
We previously characterized the splice defects induced by
a mutation in a typical splice donor site. The analyzed mu-
tation causes retinal degeneration, effects exon 5 of the BBS1
gene, and leads to both exon skipping and intron retention
(Schmid et al., 2011). Minigene assays closely resembled the
splice pattern found in patient-derived and control cell lines.
To evaluate the effect of different sequence alterations on
splicing of this SD, minigenes were mutated at nine positions
(Table 1). All of these positions are relevant to the interaction
with U1 (Fig. 1) (Zhuang and Weiner, 1986; Lund and Kjems,
2002). The minigenes were co-transfected with constructs
expressing either wild-type U1 or empty vector (Fig. 2).
Splicing of transcripts was analyzed by RT-PCR (Fig. 2A and
B). Minigenes mutated at positions - 3 and + 6 of the SD did
not reveal obvious alterations in splicing. In contrast, muta-
tions at positions - 2 through + 5 showed a reduction in
correctly spliced transcripts and simultaneously caused an
increase in exon 5 skipping (Fig. 2B, panels 1 and 2). Al-
though less clear, retention of intron 5 might occasionally be
increased.
Therapeutic efficacies of U1 adaptations to correct
the pathogenic effect of different SD mutations
The majority of the nine analyzed SD mutations caused
splice defects (Fig. 1B). We tested whether increasing the
complementarity between U1 and the mutated SD is an ef-
ficient therapeutic approach for all of these nine SD posi-
tions. In total, we analyzed the therapeutic efficacy of 18
different U1 isoforms to restore splice defects that were in-
duced by nine single mutations at different positions in the
splice donor site (Table1 and Fig. 1B).
Mutated minigenes were co-transfected with U1 con-
structs either adapted to the mutation only (U1-mut -/ + n)
or with full complementarity to the mutated SD (U1-
BBS1_mut -/ + n) (Table 1, Fig. 2B). Splice defects induced
by mutations at positions - 2, + 3, and + 4 were partially
corrected by the corresponding single-adapted U1-mut iso-
forms (Fig. 2B, panel 3). In contrast, the different fully
adapted U1-BBS1_mut isoforms completely restored normal
splicing for mutations at positions - 2, - 1, + 3, and + 4 (Fig.
2B, panel 4; Table 2). In general, U1-BBS1_mut isoforms were
more efficient to restore splice defects than U1-mut isoforms
(Fig. 2B, panels 3 and 4). No therapeutic effect was detected
for sequence alterations at SD positions + 1 and + 2 (Fig. 2B,
panels 3 and 4; Table 2).
Interestingly, the mutation at position + 5 only showed a
partial correction of the splice defect, even after treatment
with the fully adapted U1-BBS1_mut isoform (Fig. 2B, panel
4; Table 2). The single mutation-adapted U1 showed no de-
tectable therapeutic effect. Mutations at + 5 frequently cause
splice defects (Buratti et al., 2007; Krawczak et al., 2007). Our
findings suggest that the treatment with U1 is not sufficient
to completely correct aberrant splicing induced by the + 5
mutation. It seems likely that, under these circumstances,
additional splice factors are required to efficiently recognize
the SD.
U6 adaptations to correct splice defects induced
by mutations at SD position + 5
It has been described that U6 interacts with positions + 4
to + 6 in SDs (Fig. 1) (Kandels-Lewis and Seraphin,
1993; Lesser and Guthrie, 1993). Increasing the binding
affinity of U6 to the mutated SD improved the correction
of mutation-induced splice defects. We evaluated several
adaptations of the U6 snRNA sequence with the aim to en-
hance the interaction of U6 with the studied SD (Fig. 3A).
Cells were triple transfected with the minigene mutated at
+ 5, the fully adapted U1, and an adapted U6 isoform.
Table 1. Mutations in BBS1 Minigenes and Therapeutic Adaptations of U1 snRNA
BBS1 minigenes U1 constructs U1 fully adapted constructs
ID Sequence Mutationa ID Sequenceb ID Sequenceb
BBS1-wt CCGgtgaga - U1wt CAGgtaagt - -
BBS1-mut - 3 ACGgtgaga c. 477C >A U1-mut - 3 AAGgtaagt U1-BBS1_mut - 3 ACGgtgaga
BBS1-mut - 2 CTGgtgaga c. 478C >T U1-mut - 2 CTGgtaagt U1-BBS1_mut - 2 CTGgtgaga
BBS1-mut - 1 CCAgtgaga c.479G>A U1-mut - 1 CAAgtaagt U1-BBS1_mut - 1 CCAgtgaga
BBS1-mut + 1 CCGttgaga c.479+ 1G>T U1-mut + 1 CAGttaagt U1-BBS1_mut + 1 CCGttgaga
BBS1-mut + 2 CCGgggaga c.479+ 2T >G U1-mut + 2 CAGggaagt U1-BBS1_mut + 2 CCGgggaga
BBS1-mut + 3 CCGgttaga c.479+ 3G>T U1-mut + 3 CAGgttagt U1-BBS1_mut + 3 CCGgttaga
BBS1-mut + 4 CCGgtgcga c.479+ 4A>C U1-mut + 4 CAGgtacgt U1-BBS1_mut + 4 CCGgtgcga
BBS1-mut + 5 CCGgtgata c.479+ 5G>T U1-mut + 5 CAGgtaatt U1-BBS1_mut + 5 CCGgtgata
BBS1-mut + 6 CCGgtgagc c.479+ 6A>C U1-mut + 6 CAGgtaagc U1-BBS1_mut + 6 CCGgtgagc
aReference sequence NM_024649.
bFor comparability, the target sequence recognized by the adapted U1 snRNA is shown.
Bold letters indicate altered nucleotides; uppercase letters indicate exonic nucleotides; and lowercase letters indicate intronic nucleotides.
U1 snRNA, U1 small nuclear RNA.
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RT-PCR analysis revealed either partial or complete correc-
tion of the splice defect (Fig. 3B). The therapeutic efficacy was
depending on the level of complementarity between U6 and
the mutated SD. Compared to treatments with adapted U1
only, an increased amount of correctly spliced transcripts and
a simultaneous reduction of intron 5 retention was detected
by applying those U6 constructs that are complementary to
either position + 5 (U6+ 5) or + 4 and + 5 (U6+ 4/5). More-
over, the RT-PCR analysis suggested a nearly complete cor-
rection of the splice defect by adaptation of positions + 5 and
+ 6 (U6+ 5/6) or + 4, + 5, and + 6 (U6+ 4/5/6). Other U1 and
U6 combinations had no detectable effect on splicing (Fig. 3B).
The changes in the splice pattern were quantitatively
assessed (Fig. 3C and D). In reference to the wild type U6,
the adapted U6 + 5 isoform resulted in two to three times
higher levels of correctly spliced transcripts (Fig. 3C). In-
creasing the complementarity of U6 at positions + 4/ + 5
and/or + 5/ + 6 resulted in five to nine times higher levels
of correct splicing (Fig. 3C). U6 isoforms without the com-
plementary base pair at position + 5 resulted in a loss of the
therapeutic effect (Fig. 3C). Interestingly, U6 + 5 and U6 + 4/
5 significantly reduced the level of intron retention, whereas
the exon skipping band was not influenced by these treat-
ment options. In contrast, U6 + 5/6 resulted in both, sig-
nificantly reduced exon skipping and decreased levels of
intron retention (Fig. 3C). The strongest reduction in exon
skipping and intron retention was detected with the fully
adapted U6 (U6 + 4/5/6, Fig. 3C).
We further asked whether normal transcript levels can be
restored by the combined treatment with mutation-adapted
U1 and U6 (Fig. 3D). In comparison with the wild type
minigene, the U6 + 5 adaptation was able to correct approx-
imately 30% of the transcripts. Moreover, between 63 and
100% of the normal transcript levels were restored applying
either U6+ 4/5, U6+ 5/6, or U6+ 4/5/6 (Fig. 3D). In sum-
mary, our results support that the combination of mutation-
adapted U1 and U6 efficiently corrects splice defects caused
by mutations at SD position + 5.
FIG. 1. Schematic drawing of base-pair interactions be-
tween U1 snRNA, U6 snRNAs, and the splice donor site (SD)
in exon 5 of the BBS1 gene. The 5’ end of U1 interacts with
nucleotides at positions - 3 and - 1 in the exon (uppercase
letters) and with positions + 1, + 2, + 4, and + 5 in the intron
(lowercase letters), whereas U6-wt base-pairs with the SD
nucleotide at position + 5 in the intron. Base-pairing is in-
dicated by vertical lines. Pseudouridines are shown as italic
letters.
FIG. 2. Analysis and U1-based treatment of mutation-
induced splice defects in BBS1. (A) Graphical illustration of
the pSPL3-based minigene construct containing genomic
sequence of BBS1 spanning from intron 4 to 7. The vector-
derived exon is designated as pSPL3. The mutated splice
donor site (SD) is indicated by an asterisk. Primers used for
transcript amplification are displayed by horizontal gray
bars. Detected splice products are shown as schematic
drawings. (B) Reverse transcriptase PCR (RT-PCR) analysis
of the wild-type minigene (BBS1-wt) or minigenes carrying
single point mutations in the SD of BBS1 exon 5 (BBS1-mut
-/ + n; n denotes the mutated SD position). Splice assays
were performed by RT-PCR after co-transfection with either
wild-type U1 (U1-wt), empty vector (mock), U1 showing
complementarity specifically to the mutation (U1-mut -/
+ n), or U1 with full complementarity to all SD positions (U1-
BBS1_mut -/ + n). DNA sizes are given in base pairs (bp).
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We tested the possibility that other U6 positions than + 4,
+ 5, or + 6 may be relevant for the correction of splice defects.
We evaluated additional nucleotide changes at different U6
positions, but did not detect significantly altered levels of
splice variants (Fig. 4). These observations confirm that in-
creasing the U6 binding to positions + 4, + 5, and + 6 has the
highest therapeutic potential to correct splice defects.
In combination with wild-type U1, none of the U6 iso-
forms showed clear correction of the splice defects (Fig. 5).
This suggests that a treatment with adapted U6 alone is not
sufficient to overcome the deleterious effects of SD mutations
at intronic position + 5.
Side effects of the U1/U6 treatment
The adaptation of binding sites in U1 and U6 may interfere
with splicing of off-target pre-mRNAs. Using RT-PCR, we
analyzed six disease-associated off-target transcripts that
contained strong binding sites for the adapted U1 and/or U6
described herein (Supplementary Fig. 1). We did not detect
splice alterations in these transcripts, suggesting that massive
missplicing is not induced by the treatment.
Discussion
Defects in the splicing have been associated with many
inherited human diseases. Independent of the disease-
causing gene, 15% to 20% of all mutations are usually found
in splice sites and affect splicing of the pre-mRNA (Krawczak
et al., 1992; Krawczak et al., 2007). Several therapeutic inter-
ventions targeting aberrant transcripts have been investi-
gated in order to restore correct splicing (for reviews, see
Cooper et al., 2009, and Wang and Cooper, 2007). This in-
volves application of pharmacological reagents or antisense
oligonucleotides that block or increase exon inclusion. Fur-
thermore, the usage of specific siRNAs and antibodies to
reduce the amount of aberrantly spliced products has been
reported. We have recently demonstrated that increasing the
complementarity of U1 to the mutated SD is an efficient
therapeutic approach to correct splice defects in primary
human skin fibroblasts derived from patients with eye dis-
eases (Glaus et al., 2011; Schmid et al., 2011).
SD consensus sequences are identical between mice and
human and show perfect sequence complementarity to the
U1 binding sequence at nine bp (Ast, 2004; Yeo et al., 2004).
Previous studies showed that five to six matching bp be-
tween U1 and the SD are sufficient for correct splicing
(Ketterling et al., 1999). In the wild-type SD of BBS1 exon 5,
U1 matches to the highly conserved nucleotides at positions
+ 1, + 2, and also to positions - 3, - 1, + 4, and + 5. This
indicates that the correct recognition of exon 5 in BBS1 re-
quires six Watson-Crick bp with U1.
Not all positions of the SD are equally important to enable
the recognition by U1 and to ensure correct splicing. Fur-
thermore, various bp combinations within the SD show in-
creased binding to U1, indicating mutual relationships
between specific nucleotides of the SD. In our study, defects
in splicing were not induced by mutations at positions - 3
and + 6. Indeed, + 6 is among the less conserved positions in
the SD (Carmel et al., 2004), indicating that mutations at + 6
frequently have no effect on splicing. Nucleotide position - 3
appears to be more conserved. Nevertheless, nucleotides at
- 3 are frequently not conserved if the SD matches U1 at
positions - 1 and + 5, but does not show sequence comple-
mentarity at position - 2 (Burge and Karlin, 1997). The SD of
BBS1 exon 5 studied here exhibits exactly this configuration,
which might explain why the mutation at position - 3
caused no obvious defect in transcript splicing. In contrast,
all other mutations at the SD caused various degrees of exon
skipping. The mutation at - 2 may be considered a mild
mutation since it produced a detectable amount of normal
transcripts in addition to exon skipping. Furthermore, pub-
lished data are in agreement with our findings, demon-
strating a higher degree of aberrant splicing caused by the
mutation at - 1 compared to the mutation at - 2 (Carmel
et al., 2004). In summary, the studied exon–intron border can
be considered a typical splice donor site.
The efficacy of the U1-based therapeutic approach to re-
store the splice defects seems to reflect the pathogenic po-
tential of the SD mutation to affect splicing. Defects in
splicing caused by mutations at positions - 2, - 1, + 3, and
+ 4 were completely corrected by fully adapted U1 isoforms,
whereas single adapted U1 partially restored aberrant
splicing. These results suggest that high binding affinities
between U1 and the mutated SD are beneficial to achieve
complete correction of the splice defect.
Aberrant splicing activated by mutations at + 1 and + 2
could not be restored. Almost all human introns contain the
GT dinucleotide at position + 1 to + 2, two residues that are
essential for correct splicing of transcripts (Sheth et al., 2006).
Hartmann et al. (2010) reported restoration of normal splic-
ing using U1, which was only adapted to a single mutation at
SD position + 1. In this case, U1-wt already shows eight bp
complementary to the SD of the affected exon indicating a
strong interaction. However, further studies will be required
to evaluate whether splice defects derived from mutations at
+ 1 and + 2 are a suitable target for U1-based therapies.
Only partial correction of the splice defect caused by the
mutation at position + 5 was found upon treatment with
Table 2. Summary of Results Obtained After U1-based Correction of Splice Defects
BBS1 minigenes/U1 variants No correction Partial correction Complete correction
BBS1-mut - 2/U1-BBS1_mut - 2 X
BBS1-mut - 1/U1-BBS1_mut - 1 X
BBS1-mut + 1/U1-BBS1_mut + 1 X
BBS1-mut + 2/U1-BBS1_mut + 2 X
BBS1-mut + 3/U1-BBS1_mut + 3 X
BBS1-mut + 4/U1-BBS1_mut + 4 X
BBS1-mut + 5/U1-BBS1_mut + 5 X
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fully adapted U1. Similar as the GT nucleotides at the be-
ginning of introns, the G nucleotide at position + 5 in the SD
is conserved (Carmel et al., 2004). Mutations at position + 5
have frequently been found to cause aberrant splicing
(Krawczak et al., 2007), e.g., can cause Stickler syndrome
(Richards et al., 2010; Richards et al., 2012) or autosomal
dominant polycystic kidney disease (Wang et al., 2009). The
human gene mutation database lists + 5 SD mutations in the
majority of disease-associated genes. These findings sub-
stantiate the importance of developing treatment options for
diseases caused by + 5 mutations in SD. Our findings indi-
cate that the U1 treatment only partially corrects splice de-
fects induced by these mutations and suggest that additional
factors need to be modified to achieve complete correction of
the splice defect. Indeed, it has been reported previously that
U6 is essential for accurate performance of the splicing
FIG. 3. Combined treatment of mutation-adapted U1 and U6 to correct splice defects. (A) Schematic drawing of U1 and U6
binding to the splice donor site (SD) mutated at position + 5. U1 shows full complementarity to the nine nucleotides in the
mutated SD (U1-BBS1_mut + 5). We have changed the complementarity of wild-type U6 (U6-wt) to the mutated SD by
introducing alterations into its SD binding sequence (U6 +n). Modifications of U6 are shown as bold letters. (B) RT-PCR
analysis of splice defects in cells treated with U1-BBS1_mut + 5 and either U6-wt, empty vector (mock), or differently adapted
U6 isoforms (U6 +n). The wild-type minigene (BBS1-wt) or the BBS1-mut + 5 minigene in combination with U1-wt and U6-wt
were used as controls. DNA sizes are given in base pairs (bp). (C) Semi-quantitative analysis of splice patterns. Exon
skipping, correctly spliced BBS1 transcripts, and intron retention were quantified in samples treated with a combination of
fully adapted U1 (U1-BBS1_mut + 5) and different U6 isoforms (U6 +n). The amount of each splicing product was normalized
to the level measured in samples co-treated with U1-BBS1_mut + 5 and U6-wt. These values are set to 1 and indicated as a
horizontal line in each diagram. (D) Quantitative assessment of correctly spliced transcripts. In reference to the level of
normal transcripts detected in the wild-type minigene (set to 1, indicated by a horizontal bar), the efficacy of the combined U1
and U6 treatment was measured. U1-BBS1_mut + 5 was applied in combination with different adapted U6 isoforms to a
minigene carrying a mutation at the SD position + 5. Error bars in (C) and (D) represent confidence intervals (CI) of 95%,
calculated from eight independent experiments. Results of the quantification and CI are indicated above each bar.
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process mediated by its interaction with SD positions + 4,
+ 5, and + 6 (Kandels-Lewis and Seraphin, 1993; Lesser and
Guthrie, 1993; Hwang and Cohen, 1996). Clearly improved
exon recognition upon co-treatment with both adapted U1
and U6 isoforms was found. Interestingly, only the combi-
nation of adapted U1 and U6 resulted in an almost complete
correction of the splice defect, whereas a treatment with U6
isoforms alone, i.e., without the help of fully adapted U1, had
no significant effect. It is unclear whether these two splice
factors collaborate on a molecular basis or whether changes
in the kinetics of the splice mechanism lead to the observed
therapeutic effects.
Additional studies are required to substantiate the search
for possible side effects of the U1 and U6 treatment. We did
not detect that the adapted splice factors U1 and U6 interfere
with splicing of off-target pre-mRNAs, suggesting that
massive missplicing is not induced by the treatment de-
scribed herein. This finding is also confirmed by studies that
successfully applied the U1-based treatment to patient-
derived cell lines (Hartmann et al., 2010; Schmid et al., 2011).
Nevertheless, further data are required to evaluate splice
alterations in off-target transcripts on a broader basis. Ap-
plicability and safety of the therapeutic approach should be
tested also in in vivo models affected by SD mutations. A
global survey of pre-mRNA splicing in treated tissues or
organs will help to determine the balance between thera-
peutic benefits and side effects.
In summary, the treatment with U1 and U6 splice factors
shows strong potentials in the gene therapy of mutations at
SDs. Our results will have implications on the development
of therapeutic approaches applicable to many different in-
herited diseases.
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